Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics and preoperative treatmentsa

From: Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy

  CD0 group (n = 61) CD1/2 group (n = 44) CD3/4 group (n = 10) Total (n = 115) P Value
Ageb (year) 56.0 (27.0–78.0) 56.0 (26.0–76.0) 58.5 (41.0–75.0) 56.0 (26.0–78.0) 0.467
Gender      0.452
     Male 36 (59.0) 31 (70.5) 7 (70.0) 74 (64.3)  
     Female 25 (41.0) 13 (29.5) 3 (30.0) 41 (35.7)  
BMI before surgeryb (kg/m2) 21.9 (17.3–30.7) 23.1 (17.1–32.4) 21.1 (16.9–29.0) 22.3 (16.9–32.4) 0.272
Tumor location      0.109
     Proximal one-third 12 (19.7) 21 (47.7) 2 (20.0) 35 (30.4)  
     Middle one-third 18 (29.5) 8 (18.2) 3 (30.0) 29 (25.2)  
     Distal one-third 23 (37.7) 12 (27.3) 4 (40.0) 39 (33.9)  
     Whole 8 (13.1) 3 (6.8) 1 (10.0) 12 (10.4)  
Preoperative treatment      0.881
     PCT 50 (82.0) 34 (77.3) 8 (80.0) 92 (80.0)  
     PCRT 11 (18.0) 10 (22.7) 2 (20.0) 23 (20.0)  
     Cyclesb 5.0 (2.0–20.0) 7.0 (2.0–19.0) 7.5 (2.0–21.0) 5.0 (2.0–21.0) 0.082
     Durationb (month) 3.1 (1.2–15.6) 4.5 (1.2–18.0) 5.4 (1.2–15.2) 3.6 (1.2–18.0) 0.061
     Interval timeb (month) 1.1 (0.4–5.7) 1.0 (0.4–4.5) 1.2 (0.5–2.4) 1.1 (0.4–5.7) 0.167
Chemotherapy regimen      0.922
     Platinum-containing 38 (62.3) 25 (56.8) 8 (80.0) 71 (61.7)  
     Taxane-containing 7 (11.5) 6 (13.6) 1 (10.0) 14 (12.2)  
     Containing both platinum and taxane 14 (23.0) 11 (25.0) 1 (10.0) 26 (22.6)  
     Others 2 (3.3) 2 (4.5) 0 (0.0) 4 (3.5)  
Postoperative hospital stayb (day) 8.0 (5.0–12.0) 10.0 (7.0–27.0) 19.0 (11.0–29.0) 9.0 (5.0–29.0) <0.001
  1. BMI body mass index, PCRT preoperative chemoradiotherapy, PCT, preoperative chemotherapy
  2. aData are presented as number (percentage) unless indicated otherwise
  3. bData are presented as median (range)